ETF-Investor

AMGN Amgen

$438.82-1.14%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-1.14%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE 25.44×

TTM PE 25.44× · 86.25%
0%25%50%75%100%

Actual history 19.97Y · 240 month-end samples · 2006-11-30 — 2026-10-30

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1997-01-312026-10-30

PB 16.54×

PB 16.54× · 76.25%
0%25%50%75%100%

Actual history 19.97Y · 240 month-end samples · 2006-11-30 — 2026-10-30

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1997-01-312026-10-30

03Earnings outlook

Forward PE27.73×
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
ABBV——Business overlap————————
ARGX——Business overlap————————
GILD——Business overlap————————
JNJ——Business overlap————————
MRK——Business overlap————————
PFE——Business overlap————————
REGN——Business overlap————————
BIIB——Similar business————————
LLY——Similar business————————
UTHR——Similar business————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Develops, manufactures and sells biologic and other therapeutic products.

How it earns money
Sells medicines for bone disease, inflammation, cancer and rare diseases, including some biosimilars.

Why customers choose it · Research perspective
Manufacturing, evidence and payer access influence adoption. Patent expiry and competition can erode prices.

What to watch next · Research perspective
Watch volumes and prices of key products, trial milestones and sales mix to assess replacement growth.

Sources

Amgen · SEC filings index

Futu · Amgen company profile

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.